درباره این اپیزود
At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis.
انگلیسی
ایالات متحده آمریکا
رونوشت 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
جستجوی اپیزودهای گذشته
اپیزودهای قبلی EHA 2015 را جستجو کن.
قسمت های دیگر در این پادکست
Prof Anton Hagenbeek (Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about immunoconjugates, the latest targeted treatments in Hodgkin's lymphoma. He also suggests that patients with Hodgkin's disease partake in clinical trials.
ecan…
Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants.
The researchers …
Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به ecancer است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
